Anthem Biosciences IPO allotment status is the talk of the town for investors eagerly awaiting updates on their share applications. With the IPO subscription window closing on July 16, 2025, the allotment process is expected to be finalized today, July 17, 2025. The grey market premium (GMP) has soared to around 25%, signaling strong investor enthusiasm and potential listing gains. If you’re wondering how to check your Anthem Biosciences IPO allotment status online or curious about what the GMP surge implies for your investment, this comprehensive guide has you covered.
In this article, we’ll walk you through the step-by-step process to check your allotment status, dive into the significance of the GMP, and provide insights into Anthem Biosciences’ financials and market positioning. Whether you’re a retail investor, a high net-worth individual (HNI), or simply exploring the IPO landscape, this guide offers actionable steps and expert analysis to keep you informed.
What Is the Anthem Biosciences IPO?
Overview of Anthem Biosciences Limited
Founded in 2006, Anthem Biosciences Limited is a Bengaluru-based Contract Research, Development, and Manufacturing Organization (CRDMO). It provides end-to-end solutions for global pharmaceutical and biotech clients, from drug discovery to commercial-scale manufacturing. The company serves over 550 clients across 44 countries, including major markets like the US, Europe, and Japan. Anthem specializes in fermentation-based active pharmaceutical ingredients (APIs), probiotics, enzymes, peptides, and biosimilars, positioning it as a leader in India’s rapidly growing CRDMO market, projected to reach $15.4 billion by 2029 at a 13.4% CAGR.
IPO Details and Timeline
The Anthem Biosciences IPO, which opened for subscription on July 14, 2025, and closed on July 16, 2025, is a 100% Offer for Sale (OFS) worth ₹3,395 crore, involving 5.96 crore equity shares. The price band was set at ₹540–₹570 per share, with a minimum lot size of 26 shares, requiring a minimum investment of ₹14,040 for retail investors. The IPO is managed by JM Financial Limited, Citigroup Global Markets India, J.P. Morgan India, and Nomura Financial Advisory, with KFin Technologies Limited as the registrar. Shares are set to list on the BSE and NSE on July 21, 2025.
Here’s a quick look at the IPO timeline:
| Event | Date
| IPO Subscription Period | July 14–16, 2025
| Allotment Finalization | July 17, 2025
| Refund/Credit to Demat | July 18, 2025
| Listing Date | July 21, 2025
The IPO saw overwhelming demand, with an overall subscription of 63.86–67.42 times, driven by Qualified Institutional Buyers (QIBs) at 182.65 times, Non-Institutional Investors (NIIs) at 42.36–44.70 times, and retail investors at 5.64–5.98 times.
How to Check Anthem Biosciences IPO Allotment Status Online
Investors can check their Anthem Biosciences IPO allotment status through multiple platforms, including the BSE, NSE, and KFin Technologies websites. Below are step-by-step instructions for each method.
Method 1: Check Allotment Status on BSE
- Visit the BSE website: https://www.bseindia.com/investors/appli_check.aspx.
- Select “Equity” under the issue type.
- Choose “Anthem Biosciences Limited” from the dropdown menu.
- Enter your Application Number or PAN.
- Verify by ticking the “I am not a robot” box and click “Search.”
- Your allotment status will be displayed on the screen.
Method 2: Check Allotment Status on NSE
- Go to the NSE IPO allotment page: https://www.nseindia.com/invest/check-trades-bids-verify-ipo-bids.
- Select the “Equity & SME IPO bid details” option.
- Enter your PAN or Application Number.
- Click “Submit” to view your Anthem Biosciences IPO allotment status.
Method 3: Check Allotment Status on KFin Technologies
- Visit the KFin Technologies IPO status page: https://kosmic.kfintech.com/ipostatus/.
- Select “Anthem Biosciences Limited” from the dropdown menu.
- Choose one of the following: Application Number, Demat Account, or PAN.
- Enter the required details and click “Search” to view your allotment status.
Pro Tip: Ensure you have your PAN or application number handy. If you applied through a broker like Zerodha, Upstox, or 5Paisa, you can also check the status via their apps or websites.
Understanding the 25% GMP Surge
What Is Grey Market Premium (GMP)?
The Grey Market Premium (GMP) reflects the price at which IPO shares trade in the unofficial grey market before listing. It’s an indicator of investor sentiment and expected listing performance but isn’t regulated, so it carries risks. As of July 17, 2025, the GMP for Anthem Biosciences IPO ranged from ₹144 to ₹158, suggesting an estimated listing price of ₹714–₹728 per share. This translates to a potential listing gain of 25.26–27.37% over the issue price of ₹570.
Why Is the GMP Surging?
The 25% GMP surge reflects strong market enthusiasm, driven by:
- High Subscription Rates: The IPO’s oversubscription, particularly by QIBs (182.65 times), signals robust institutional confidence.
- Strong Financials: Anthem Biosciences reported a 30% revenue growth to ₹1,930.29 crore and a 23% profit after tax (PAT) increase to ₹451.26 crore in FY25.
- Market Positioning: As India’s largest CRDMO by fermentationbudgets, Anthem’s integrated capabilities in small and large molecules make it a unique player in a high-growth industry.
- Positive Broker Recommendations: Brokerages like SBI Securities and Anand Rathi have given a “Subscribe” rating, citing Anthem’s strong fundamentals and fair pricing compared to peers.
Case Study: The 2024 IPO of Syrma SGS Technology saw a similar GMP surge of 20–25% before listing, driven by strong fundamentals and market demand. It listed at a 22% premium, rewarding investors who relied on GMP as a sentiment gauge but conducted thorough due diligence. Anthem’s GMP trend suggests a comparable outcome, though investors should remain cautious of market volatility.
Image Suggestion: Include a chart showing Anthem Biosciences’ GMP trend from July 9 (₹67) to July 17 (₹158) to visually represent the surge in investor interest.
Why Anthem Biosciences IPO Is a Hot Pick
Financial Performance
Anthem Biosciences has demonstrated robust financial growth:
- Revenue: ₹1,930.29 crore in FY25, up 30% from ₹1,483.07 crore in FY24.
- Profit After Tax (PAT): ₹451.26 crore in FY25, a 23% increase from ₹367.31 crore in FY24.
- EBITDA Margin: 36.81%, the highest among Indian peers, reflecting operational efficiency.
- Return on Equity (ROE): 20.82%, and Return on Capital Employed (ROCE): 26.88%, showcasing strong profitability.
The company’s revenue CAGR of 30.5% over three years and a P/E ratio of 70.9x (based on FY25 earnings) indicate a premium valuation, but analysts argue it’s justified by Anthem’s leadership in the CRDMO space and its expansion plans, including a 57% increase in custom synthesis capacity to 425 kL by FY26.
Competitive Advantages
- Integrated Capabilities: Anthem is one of the few Indian CRDMOs with expertise in both New Chemical Entities (NCEs) and New Biological Entities (NBEs), serving a diverse client base.
- Global Reach: Exports to 44 countries, with significant revenue from regulated markets like the US and Europe.
- Innovation: Holds 8 patents and has 17 patent applications pending as of March 2025.
- Client Relationships: Average 12-year relationship with top 10 clients, ensuring revenue stability.
However, risks include high client concentration (70% of revenue from five clients) and the fact that the IPO is an OFS, meaning no proceeds go to the company for growth.
Risks and Considerations for Investors
While the GMP and subscription rates are promising, investors should consider:
- High P/E Ratio: At 70.9x, Anthem’s valuation is higher than the peer average of 42.7x EV/EBITDA, suggesting a premium pricing.
- OFS Structure: The company won’t receive funds for expansion, which may limit short-term growth initiatives.
- Market Volatility: GMP is speculative and not a guaranteed predictor of listing performance.
- Client Concentration: Dependence on a few key clients poses revenue risks.
Expert Tip: Review the Red Herring Prospectus (RHP) on the SEBI website and consult a SEBI-registered financial advisor before investing.
FAQ Section
How Do I Check My Anthem Biosciences IPO Allotment Status Online?
To check your Anthem Biosciences IPO allotment status, follow these steps:
- Via BSE:
- Visit https://www.bseindia.com/investors/appli_check.aspx.
- Select “Equity” and choose “Anthem Biosciences Limited.”
- Enter your PAN or Application Number and submit.
- Results will show whether you received shares and the quantity allotted.
- Via NSE:
- Go to https://www.nseindia.com/invest/check-trades-bids-verify-ipo-bids.
- Input your PAN or Application Number and click “Submit.”
- Your status will be displayed.
- Via KFin Technologies:
- Access https://kosmic.kfintech.com/ipostatus/.
- Select “Anthem Biosciences Limited” and enter your PAN, Application Number, or Demat Account details.
- The status will appear on the screen.
If you applied through brokers like Zerodha or Upstox, check their platforms for updates. Allotment was finalized on July 17, 2025, with shares credited to demat accounts by July 18. Refunds for non-allotted applicants are also processed on July 18.
What Does the 25% GMP Surge Indicate for Anthem Biosciences IPO?
The 25% GMP surge, reported at ₹144–₹158 as of July 17, 2025, suggests strong investor optimism about Anthem Biosciences’ listing performance. With a price band of ₹570, the estimated listing price is ₹714–₹728, indicating a potential 25–27.37% gain. This reflects high demand, evidenced by the IPO’s 63.86–67.42 times oversubscription. However, GMP is unregulated and speculative, so investors should analyze Anthem’s fundamentals, such as its 30% revenue growth and 36.81% EBITDA margin, alongside risks like high client concentration and a 70.9x P/E ratio. Always review the RHP and consult financial advisors.
When Will Anthem Biosciences Shares Be Listed, and What Should I Expect?
Anthem Biosciences shares are expected to list on the BSE and NSE on July 21, 2025. Based on the GMP of ₹144–₹158, the listing price could be ₹714–₹728, offering a 25–27.37% premium over the ₹570 issue price. The IPO’s strong subscription (63.86–67.42 times) and Anthem’s robust financials (₹1,930.29 crore revenue, 23% PAT growth in FY25) support this optimism. However, market conditions on listing day could affect performance, and the OFS structure means no fresh capital for the company. Monitor market trends and seek expert advice before deciding to hold or sell.
Is Anthem Biosciences IPO a Good Investment?
Anthem Biosciences IPO offers exposure to a leading CRDMO with a 30.5% revenue CAGR and a 36.81% EBITDA margin, making it attractive for long-term investors. Its unique capabilities in NCEs and NBEs, global client base, and expansion plans (57% capacity increase by FY26) are strengths. However, the high P/E ratio (70.9x), client concentration risk, and OFS structure warrant caution. Brokerages like SBI Securities recommend subscribing for long-term gains, citing fair pricing compared to peers. Review the RHP, assess your risk tolerance, and consult a financial advisor to align with your investment goals.
What Are the Risks of Investing in Anthem Biosciences IPO?
Key risks include:
- High Valuation: A 70.9x P/E ratio exceeds the peer average, potentially limiting upside if growth expectations falter.
- OFS Structure: No proceeds go to the company, restricting funds for expansion.
- Client Concentration: Over 70% of revenue comes from five clients, posing dependency risks.
- Market Volatility: GMP-based gains (25–27%) aren’t guaranteed, as listing performance depends on market conditions.
Balance these with Anthem’s strong financials and industry leadership before investing. Consult the RHP and a financial advisor.
How Was the Subscription Demand for Anthem Biosciences IPO?
The IPO was subscribed 63.86–67.42 times, with:
- QIBs: 182.65 times, reflecting strong institutional interest.
- NIIs: 42.36–44.70 times, showing HNI enthusiasm.
- Retail: 5.64–5.98 times, indicating moderate retail participation.
This high demand, coupled with a GMP of ₹144–₹158, suggests a favorable listing outlook, though investors should remain cautious of market risks.
Conclusion
The Anthem Biosciences IPO allotment status is a critical milestone for investors, with finalization on July 17, 2025, and a listing scheduled for July 21. The 25% GMP surge underscores strong market sentiment, driven by Anthem’s robust financials, leadership in the CRDMO space, and high subscription rates. By following the steps outlined to check your allotment status and understanding the implications of the GMP, you can make informed decisions about your investment.
Have you applied for the Anthem Biosciences IPO? Share your thoughts on the GMP surge or ask questions in the comments below! For more IPO updates, subscribe to our newsletter or follow us on social media.